Corporate News

2022

Director Dealing

Oct 11, 2019, 07:56 AM by felicity.hopkins ICOM

Polarean Imaging plc (AIM: POLX), the medical-imaging technology company, with a proprietary drug-device combination product, announces that it was notified on 10 October 2019 that Dr Jonathan Allis, a Non-Executive Director of the Company, purchased 1,540,000 Ordinary Shares of £0.00037 ("Ordinary Shares") at a price of 13.06 pence per share on 8 October 2019.

Following this transaction, Dr Allis now holds a beneficial interest in 1,540,000 Ordinary Shares, representing approximately 1.35 per cent. of the Company's issued share capital.

 

Enquiries:

Polarean Imaging plc www.polarean.com/www.polarean-ir.com
Richard Hullihen, Chief Executive Officer Via Walbrook PR
Richard Morgan, Chairman
SP Angel Corporate Finance LLP Tel: +44 (0)20 3470 0470
David Hignell / Lindsay Mair / Jamie Spotswood (Corporate Finance)
Vadim Alexandre / Rob Rees (Corporate Broking)
Walbrook PR Tel: +44 (0)20 7933 8780
or[email protected]
Anna Dunphy / Paul McManus Mob: +44 (0)7879 741 001 / +44 (0)7980 541 893

 

Market Abuse Regulation (MAR) Disclosure

Certain information contained in this announcement would have been deemed inside information for the purposes of Article 7 of Regulation (EU) No 596/2014 until the release of this announcement.

NOTIFICATION AND PUBLIC DISCLOSURE OF TRANSACTIONS BY PERSONS DISCHARGING MANAGERIAL RESPONSIBILITIES AND PERSONS CLOSELY ASSOCIATED WITH THEM:


1. Details of the person discharging managerial responsibilities/person closely associated
a) Name: Dr Jonathan Allis
2. Reason for the notification
a) Position/status: Non-Executive Director
b) Initial notification/Amendment: Initial notification
3. Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor
a) Name: Polarean Imaging Plc
b) LEI: 213800DGR2BHXJ36OL37
4. Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transactions have been conducted
a) Description of the financial instrument, type of instrument: Identification code: Ordinary shares of £0.00037

GB00BF3DT583
b) Nature of the transaction: Purchase of shares
c) Price(s) and volume(s):
Price(s) Volume(s)
13.06 pence 1,540,000
d) Aggregated information: Aggregated volume: Price: Single transaction as in 4 c) above
Price(s) Volume(s)
13.06 pence 1,540,000
e) Date of the transaction: 15.48hrs on 8 October 2019
f) Place of the transaction: Outside a trading venue

 

Load more comments
Comment by from

2021

Director Dealing

Oct 11, 2019, 07:56 AM by felicity.hopkins ICOM

Polarean Imaging plc (AIM: POLX), the medical-imaging technology company, with a proprietary drug-device combination product, announces that it was notified on 10 October 2019 that Dr Jonathan Allis, a Non-Executive Director of the Company, purchased 1,540,000 Ordinary Shares of £0.00037 ("Ordinary Shares") at a price of 13.06 pence per share on 8 October 2019.

Following this transaction, Dr Allis now holds a beneficial interest in 1,540,000 Ordinary Shares, representing approximately 1.35 per cent. of the Company's issued share capital.

 

Enquiries:

Polarean Imaging plc www.polarean.com/www.polarean-ir.com
Richard Hullihen, Chief Executive Officer Via Walbrook PR
Richard Morgan, Chairman
SP Angel Corporate Finance LLP Tel: +44 (0)20 3470 0470
David Hignell / Lindsay Mair / Jamie Spotswood (Corporate Finance)
Vadim Alexandre / Rob Rees (Corporate Broking)
Walbrook PR Tel: +44 (0)20 7933 8780
or[email protected]
Anna Dunphy / Paul McManus Mob: +44 (0)7879 741 001 / +44 (0)7980 541 893

 

Market Abuse Regulation (MAR) Disclosure

Certain information contained in this announcement would have been deemed inside information for the purposes of Article 7 of Regulation (EU) No 596/2014 until the release of this announcement.

NOTIFICATION AND PUBLIC DISCLOSURE OF TRANSACTIONS BY PERSONS DISCHARGING MANAGERIAL RESPONSIBILITIES AND PERSONS CLOSELY ASSOCIATED WITH THEM:


1. Details of the person discharging managerial responsibilities/person closely associated
a) Name: Dr Jonathan Allis
2. Reason for the notification
a) Position/status: Non-Executive Director
b) Initial notification/Amendment: Initial notification
3. Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor
a) Name: Polarean Imaging Plc
b) LEI: 213800DGR2BHXJ36OL37
4. Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transactions have been conducted
a) Description of the financial instrument, type of instrument: Identification code: Ordinary shares of £0.00037

GB00BF3DT583
b) Nature of the transaction: Purchase of shares
c) Price(s) and volume(s):
Price(s) Volume(s)
13.06 pence 1,540,000
d) Aggregated information: Aggregated volume: Price: Single transaction as in 4 c) above
Price(s) Volume(s)
13.06 pence 1,540,000
e) Date of the transaction: 15.48hrs on 8 October 2019
f) Place of the transaction: Outside a trading venue

 

Load more comments
Comment by from

2020

Director Dealing

Oct 11, 2019, 07:56 AM by felicity.hopkins ICOM

Polarean Imaging plc (AIM: POLX), the medical-imaging technology company, with a proprietary drug-device combination product, announces that it was notified on 10 October 2019 that Dr Jonathan Allis, a Non-Executive Director of the Company, purchased 1,540,000 Ordinary Shares of £0.00037 ("Ordinary Shares") at a price of 13.06 pence per share on 8 October 2019.

Following this transaction, Dr Allis now holds a beneficial interest in 1,540,000 Ordinary Shares, representing approximately 1.35 per cent. of the Company's issued share capital.

 

Enquiries:

Polarean Imaging plc www.polarean.com/www.polarean-ir.com
Richard Hullihen, Chief Executive Officer Via Walbrook PR
Richard Morgan, Chairman
SP Angel Corporate Finance LLP Tel: +44 (0)20 3470 0470
David Hignell / Lindsay Mair / Jamie Spotswood (Corporate Finance)
Vadim Alexandre / Rob Rees (Corporate Broking)
Walbrook PR Tel: +44 (0)20 7933 8780
or[email protected]
Anna Dunphy / Paul McManus Mob: +44 (0)7879 741 001 / +44 (0)7980 541 893

 

Market Abuse Regulation (MAR) Disclosure

Certain information contained in this announcement would have been deemed inside information for the purposes of Article 7 of Regulation (EU) No 596/2014 until the release of this announcement.

NOTIFICATION AND PUBLIC DISCLOSURE OF TRANSACTIONS BY PERSONS DISCHARGING MANAGERIAL RESPONSIBILITIES AND PERSONS CLOSELY ASSOCIATED WITH THEM:


1. Details of the person discharging managerial responsibilities/person closely associated
a) Name: Dr Jonathan Allis
2. Reason for the notification
a) Position/status: Non-Executive Director
b) Initial notification/Amendment: Initial notification
3. Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor
a) Name: Polarean Imaging Plc
b) LEI: 213800DGR2BHXJ36OL37
4. Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transactions have been conducted
a) Description of the financial instrument, type of instrument: Identification code: Ordinary shares of £0.00037

GB00BF3DT583
b) Nature of the transaction: Purchase of shares
c) Price(s) and volume(s):
Price(s) Volume(s)
13.06 pence 1,540,000
d) Aggregated information: Aggregated volume: Price: Single transaction as in 4 c) above
Price(s) Volume(s)
13.06 pence 1,540,000
e) Date of the transaction: 15.48hrs on 8 October 2019
f) Place of the transaction: Outside a trading venue

 

Load more comments
Comment by from

2019

Director Dealing

11 October 2019

Polarean Imaging plc (AIM: POLX), the medical-imaging technology company, with a proprietary drug-device combination product, announces that it was notified on 10 October 2019 that Dr Jonathan Allis, a Non-Executive Director of the Company, purchased 1,540,000 Ordinary Shares of £0.00037 ("Ordinary Shares") at a price of 13.06 pence per share on 8 October 2019.

Following this transaction, Dr Allis now holds a beneficial interest in 1,540,000 Ordinary Shares, representing approximately 1.35 per cent. of the Company's issued share capital.

 

Enquiries:

Polarean Imaging plc www.polarean.com/www.polarean-ir.com
Richard Hullihen, Chief Executive Officer Via Walbrook PR
Richard Morgan, Chairman
SP Angel Corporate Finance LLP Tel: +44 (0)20 3470 0470
David Hignell / Lindsay Mair / Jamie Spotswood (Corporate Finance)
Vadim Alexandre / Rob Rees (Corporate Broking)
Walbrook PR Tel: +44 (0)20 7933 8780
or[email protected]
Anna Dunphy / Paul McManus Mob: +44 (0)7879 741 001 / +44 (0)7980 541 893

 

Market Abuse Regulation (MAR) Disclosure

Certain information contained in this announcement would have been deemed inside information for the purposes of Article 7 of Regulation (EU) No 596/2014 until the release of this announcement.

NOTIFICATION AND PUBLIC DISCLOSURE OF TRANSACTIONS BY PERSONS DISCHARGING MANAGERIAL RESPONSIBILITIES AND PERSONS CLOSELY ASSOCIATED WITH THEM:


1. Details of the person discharging managerial responsibilities/person closely associated
a) Name: Dr Jonathan Allis
2. Reason for the notification
a) Position/status: Non-Executive Director
b) Initial notification/Amendment: Initial notification
3. Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor
a) Name: Polarean Imaging Plc
b) LEI: 213800DGR2BHXJ36OL37
4. Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transactions have been conducted
a) Description of the financial instrument, type of instrument: Identification code: Ordinary shares of £0.00037

GB00BF3DT583
b) Nature of the transaction: Purchase of shares
c) Price(s) and volume(s):
Price(s) Volume(s)
13.06 pence 1,540,000
d) Aggregated information: Aggregated volume: Price: Single transaction as in 4 c) above
Price(s) Volume(s)
13.06 pence 1,540,000
e) Date of the transaction: 15.48hrs on 8 October 2019
f) Place of the transaction: Outside a trading venue

 

2018

Director Dealing

11 October 2019

Polarean Imaging plc (AIM: POLX), the medical-imaging technology company, with a proprietary drug-device combination product, announces that it was notified on 10 October 2019 that Dr Jonathan Allis, a Non-Executive Director of the Company, purchased 1,540,000 Ordinary Shares of £0.00037 ("Ordinary Shares") at a price of 13.06 pence per share on 8 October 2019.

Following this transaction, Dr Allis now holds a beneficial interest in 1,540,000 Ordinary Shares, representing approximately 1.35 per cent. of the Company's issued share capital.

 

Enquiries:

Polarean Imaging plc www.polarean.com/www.polarean-ir.com
Richard Hullihen, Chief Executive Officer Via Walbrook PR
Richard Morgan, Chairman
SP Angel Corporate Finance LLP Tel: +44 (0)20 3470 0470
David Hignell / Lindsay Mair / Jamie Spotswood (Corporate Finance)
Vadim Alexandre / Rob Rees (Corporate Broking)
Walbrook PR Tel: +44 (0)20 7933 8780
or[email protected]
Anna Dunphy / Paul McManus Mob: +44 (0)7879 741 001 / +44 (0)7980 541 893

 

Market Abuse Regulation (MAR) Disclosure

Certain information contained in this announcement would have been deemed inside information for the purposes of Article 7 of Regulation (EU) No 596/2014 until the release of this announcement.

NOTIFICATION AND PUBLIC DISCLOSURE OF TRANSACTIONS BY PERSONS DISCHARGING MANAGERIAL RESPONSIBILITIES AND PERSONS CLOSELY ASSOCIATED WITH THEM:


1. Details of the person discharging managerial responsibilities/person closely associated
a) Name: Dr Jonathan Allis
2. Reason for the notification
a) Position/status: Non-Executive Director
b) Initial notification/Amendment: Initial notification
3. Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor
a) Name: Polarean Imaging Plc
b) LEI: 213800DGR2BHXJ36OL37
4. Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transactions have been conducted
a) Description of the financial instrument, type of instrument: Identification code: Ordinary shares of £0.00037

GB00BF3DT583
b) Nature of the transaction: Purchase of shares
c) Price(s) and volume(s):
Price(s) Volume(s)
13.06 pence 1,540,000
d) Aggregated information: Aggregated volume: Price: Single transaction as in 4 c) above
Price(s) Volume(s)
13.06 pence 1,540,000
e) Date of the transaction: 15.48hrs on 8 October 2019
f) Place of the transaction: Outside a trading venue

 

Investor Alert

Sign up for Email Alerts